Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Firms

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Intra-Cellular Therapies, Inc. and Soleno Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 4,000% from 2014 to 2023. In contrast, Soleno Therapeutics maintained a more stable trajectory, with expenses increasing by approximately 360% over the same period.

This divergence highlights the strategic choices each company has made. While Intra-Cellular Therapies has aggressively expanded its operations, reflected in its rising costs, Soleno Therapeutics has opted for a more conservative approach. Understanding these trends offers valuable insights into how biotech firms balance growth and cost management in a rapidly evolving industry.